Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel

Ottavia Prunas, Joshua L. Warren, Forrest W. Crawford, Sivan Gazit, Tal Patalon, Daniel M. Weinberger, Virginia E. Pitzer
doi: https://doi.org/10.1101/2021.07.13.21260393
Ottavia Prunas
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University; New Haven, CT USA
2Public Health Modeling Unit, Yale School of Public Health, Yale University; New Haven, CT USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ottavia.prunas@yale.edu
Joshua L. Warren
2Public Health Modeling Unit, Yale School of Public Health, Yale University; New Haven, CT USA
3Department of Biostatistics, Yale School of Public Health, Yale University; New Haven, CT USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Forrest W. Crawford
2Public Health Modeling Unit, Yale School of Public Health, Yale University; New Haven, CT USA
3Department of Biostatistics, Yale School of Public Health, Yale University; New Haven, CT USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sivan Gazit
4Maccabi Institute for Research & Innovation, Maccabi Healthcare Services; Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tal Patalon
4Maccabi Institute for Research & Innovation, Maccabi Healthcare Services; Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel M. Weinberger
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University; New Haven, CT USA
2Public Health Modeling Unit, Yale School of Public Health, Yale University; New Haven, CT USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Virginia E. Pitzer
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University; New Haven, CT USA
2Public Health Modeling Unit, Yale School of Public Health, Yale University; New Haven, CT USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The individual-level effectiveness of vaccines against clinical disease caused by SARS-CoV-2 is well-established. However, few studies have directly examined the effect of COVID-19 vaccines on transmission. We quantified the effectiveness of vaccination with BNT162b2 (Pfizer-BioNTech mRNA-based vaccine) against household transmission of SARS-CoV-2 in Israel. We fit two time-to-event models – a mechanistic transmission model and a regression model – to estimate vaccine effectiveness against susceptibility to infection and infectiousness given infection in household settings. Vaccine effectiveness against susceptibility to infection was 80-88%. For breakthrough infections among vaccinated individuals, the vaccine effectiveness against infectiousness was 41-79%. The overall vaccine effectiveness against transmission was 88.5%. Vaccination provides substantial protection against susceptibility to infection and slightly lower protection against infectiousness given infection, thereby reducing transmission of SARS-CoV-2 to household contacts.

One-Sentence Summary Vaccination reduced both the rate of infection with SARS-CoV-2 and transmission to household contacts in Israel.

Competing Interest Statement

DMW has received consulting fees from Pfizer, Merck, GSK, and Affinivax for topics unrelated to this manuscript and is Principal Investigator on a research grant from Pfizer on an unrelated topic. VEP is a member of the WHO Immunization and Vaccine-related Research Advisory Committee (IVIR-AC) and has received reimbursement from Merck and Pfizer for travel expenses to Scientific Input Engagements unrelated to the topic of this manuscript. All other authors declare that they have no competing interests.

Funding Statement

National Institutes of Health grant R01AI137093 (JLW, DMW, VEP) National Institutes of Health grant 1DP2HD091799 (FWC) National Institutes of Health grant R01AI112970 (VEP)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was approved by the Maccabi Healthcare Services' Institutional Review Board. Informed consent was waived by the IRB, as all identifying details of the participants were removed before computational analyses. The analysis of the deidentified data was determined to be 'not human subject research' by the Yale IRB

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

According to the IMOH (Israeli Ministry of Health) regulations, individual-level data cannot be shared openly. Specific requests for remote access to deidentified data should be referred to the Maccabi Institute for Research & Innovation.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 16, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
Ottavia Prunas, Joshua L. Warren, Forrest W. Crawford, Sivan Gazit, Tal Patalon, Daniel M. Weinberger, Virginia E. Pitzer
medRxiv 2021.07.13.21260393; doi: https://doi.org/10.1101/2021.07.13.21260393
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
Ottavia Prunas, Joshua L. Warren, Forrest W. Crawford, Sivan Gazit, Tal Patalon, Daniel M. Weinberger, Virginia E. Pitzer
medRxiv 2021.07.13.21260393; doi: https://doi.org/10.1101/2021.07.13.21260393

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (941)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (418)
  • Epidemiology (8967)
  • Forensic Medicine (4)
  • Gastroenterology (417)
  • Genetic and Genomic Medicine (1938)
  • Geriatric Medicine (190)
  • Health Economics (400)
  • Health Informatics (1321)
  • Health Policy (657)
  • Health Systems and Quality Improvement (517)
  • Hematology (211)
  • HIV/AIDS (416)
  • Infectious Diseases (except HIV/AIDS) (10765)
  • Intensive Care and Critical Care Medicine (570)
  • Medical Education (199)
  • Medical Ethics (52)
  • Nephrology (221)
  • Neurology (1817)
  • Nursing (108)
  • Nutrition (271)
  • Obstetrics and Gynecology (351)
  • Occupational and Environmental Health (469)
  • Oncology (992)
  • Ophthalmology (296)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1891)
  • Public and Global Health (4107)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (361)
  • Respiratory Medicine (547)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (206)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)